Circulating endothelial progenitor cells, vascular function, and cardiovascular risk

New England Journal of Medicine

Volumn 348, Issue 7, 2003, Pages 593-600

  Hill, Jonathan M ^a   Zalos, Gloria ^a   Halcox, Julian P J ^a   Schenke, William H ^a   Waclawiw, Myron A ^a   Quyyumi, Arshed A ^b   Finkel, Toren ^a,c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ANAMNESIS; ARTICLE; ATHEROGENESIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CELL COUNT; CELL CULTURE; CELL ISOLATION; CELL MOTILITY; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ECHOGRAPHY; ENDOTHELIUM CELL; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENESCENCE; STEM CELL; VASCULAR DISEASE;

ADULT; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CELL AGING; COLONY-FORMING UNITS ASSAY; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; STEM CELLS;

EID: 0037434561     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022287     Document Type: Article

References (36)

1. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative endothelial progenitor cells for angiogenesis. Science 1997;275:964-7.
2. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7.
3. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8.
4. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337-46.
5. Murohara T, Ikeda H, Duan J, et al. Transplanted cord blood-derived endothelial progenitor cells augment postnatal neovascularization. J Clin Invest 2000;105:1527-36.
6. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-8.
7. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-72.
8. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8.
9. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-6.
10. Grant MB, May WS, Caballero S, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002;8:607-12.
11. Luttun A, Carmeliet G, Carmeliet P. Vascular progenitors: from biology to treatment. Trends Cardiovasc Med 2002;12:88-96.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
13. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
14. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
15. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6.
16. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-72.
17. Halcox JPJ, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-8.
18. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cell. Circulation 2002;105:3017-24.
19. Shi Q, Wu MH, Hayashida N, Wechezak AR, Clowes AW, Sauvage LR. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. J Vasc Surg 1994;20:546-56.
20. Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med 2001;7:1035-40.
21. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol 1987; 59:91G-94G. [Erratum, Am J Cardiol 1987; 60:All.]
22. Masuda H, Kalka C, Takahashi T, et al. Regulatory role of estrogen on endothelial progenitor cell kinetics for cyclic endometrial neovascularization. Circulation 1999;100:Suppl I:I-475. abstract.
23. Masuda H, Kalka C, Takahashi T, et al. The effect of progesterone on endothelial progenitor cell kinetics for physiological neovascularization of uterus. Circulation 1999;100:Suppl I:I-691-I-692. abstract.
24. Ito H, Kovira II, Bloom ML, et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 1999;59:5875-7.
25. Dimri GP, Lee XH, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
26. Prasad A, Halcox JPJ, Waclawiw MA, Quyyumi AA. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. J Am Coll Cardiol 2001;38:1089-95.
27. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65. [Erratum, J Am Coll Cardiol 2002; 39:1082.]
28. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399-405.
29. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-7.
30. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-90.
31. Seale P, Asakura A, Rudnicki MA. The potential of muscle stem cells. Dev Cell 2001;1:333-42.
32. Webster C, Blau HM. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat Cell Mol Genet 1990;16:557-65.
33. Decary S, Hamida CB, Mouly V, Barbet JP, Hentati F, Butler-Browne GS. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in younger children. Neuromuscul Disord 2000;10:113-20.
34. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1-E7.
35. Tyner SD, Venkatachalam S, Choi J, et al. p53 Mutant mice that display early ageing-associated phenotypes. Nature 2002;415:45-53.
36. Geiger H, Van Zant G. The aging of lympho-hematopoietic stem cells. Nat Immunol 2002;3:329-33.